covid_vs_flu: update O’Driscoll (now published in Nature)
This commit is contained in:
@@ -34,7 +34,7 @@ The COVID-19 IFR curves represent these estimates:
|
|||||||
1. [Gudbjartsson et al.: Humoral Immune Response to SARS-CoV-2 in Iceland](https://www.nejm.org/doi/full/10.1056/NEJMoa2026116),
|
1. [Gudbjartsson et al.: Humoral Immune Response to SARS-CoV-2 in Iceland](https://www.nejm.org/doi/full/10.1056/NEJMoa2026116),
|
||||||
specifically [Supplementary Appendix 1](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2026116/suppl_file/nejmoa2026116_appendix_1.pdf) (table S7)
|
specifically [Supplementary Appendix 1](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2026116/suppl_file/nejmoa2026116_appendix_1.pdf) (table S7)
|
||||||
1. [PHAS - Public Health Agency of Sweden: The infection fatality rate of COVID-19 in Stockholm – Technical report](https://www.folkhalsomyndigheten.se/contentassets/53c0dc391be54f5d959ead9131edb771/infection-fatality-rate-covid-19-stockholm-technical-report.pdf) (table B.1)
|
1. [PHAS - Public Health Agency of Sweden: The infection fatality rate of COVID-19 in Stockholm – Technical report](https://www.folkhalsomyndigheten.se/contentassets/53c0dc391be54f5d959ead9131edb771/infection-fatality-rate-covid-19-stockholm-technical-report.pdf) (table B.1)
|
||||||
1. [O’Driscoll et al.: Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries](https://www.medrxiv.org/content/10.1101/2020.08.24.20180851v1) (table S4)
|
1. [O’Driscoll et al.: Age-specific mortality and immunity patterns of SARS-CoV-2](https://www.nature.com/articles/s41586-020-2918-0) (table S3)
|
||||||
1. [Ward et al.: Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults](https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2),
|
1. [Ward et al.: Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults](https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2),
|
||||||
specifically [Supplementary Appendix](https://www.medrxiv.org/highwire/filestream/93745/field_highwire_adjunct_files/0/2020.08.12.20173690-1.docx) (table S2a, column "Based on confirmed COVID-19 deaths")
|
specifically [Supplementary Appendix](https://www.medrxiv.org/highwire/filestream/93745/field_highwire_adjunct_files/0/2020.08.12.20173690-1.docx) (table S2a, column "Based on confirmed COVID-19 deaths")
|
||||||
1. [Yang et al.: Estimating the infection fatality risk of COVID-19 in New York City during the spring 2020 pandemic wave](https://www.medrxiv.org/content/10.1101/2020.06.27.20141689v2) (table 1)
|
1. [Yang et al.: Estimating the infection fatality risk of COVID-19 in New York City during the spring 2020 pandemic wave](https://www.medrxiv.org/content/10.1101/2020.06.27.20141689v2) (table 1)
|
||||||
|
|||||||
Binary file not shown.
|
Before Width: | Height: | Size: 588 KiB After Width: | Height: | Size: 570 KiB |
+24
-22
@@ -137,27 +137,29 @@ ifrs_covid = [
|
|||||||
(90,maxage): 16.21,
|
(90,maxage): 16.21,
|
||||||
}),
|
}),
|
||||||
|
|
||||||
# O’Driscoll et al.: Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries
|
# O’Driscoll et al.: Age-specific mortality and immunity patterns of SARS-CoV-2
|
||||||
# https://www.medrxiv.org/content/10.1101/2020.08.24.20180851v1
|
# https://www.nature.com/articles/s41586-020-2918-0
|
||||||
# (table S4)
|
# Supplementary information
|
||||||
|
# https://static-content.springer.com/esm/art%3A10.1038%2Fs41586-020-2918-0/MediaObjects/41586_2020_2918_MOESM1_ESM.pdf
|
||||||
|
# (table S3)
|
||||||
('O’Driscoll', {
|
('O’Driscoll', {
|
||||||
(0,4): 0.002,
|
(0,4): 0.003,
|
||||||
(5,9): 0,
|
(5,9): 0.001,
|
||||||
(10,14): 0,
|
(10,14): 0.001,
|
||||||
(15,19): 0.002,
|
(15,19): 0.003,
|
||||||
(20,24): 0.004,
|
(20,24): 0.006,
|
||||||
(25,29): 0.009,
|
(25,29): 0.013,
|
||||||
(30,34): 0.017,
|
(30,34): 0.024,
|
||||||
(35,39): 0.029,
|
(35,39): 0.040,
|
||||||
(40,44): 0.053,
|
(40,44): 0.075,
|
||||||
(45,49): 0.086,
|
(45,49): 0.121,
|
||||||
(50,54): 0.154,
|
(50,54): 0.207,
|
||||||
(55,59): 0.241,
|
(55,59): 0.323,
|
||||||
(60,64): 0.359,
|
(60,64): 0.456,
|
||||||
(65,69): 0.642,
|
(65,69): 1.075,
|
||||||
(70,74): 1.076,
|
(70,74): 1.674,
|
||||||
(75,79): 2.276,
|
(75,79): 3.203,
|
||||||
(80,maxage): 7.274,
|
(80,maxage): 8.292,
|
||||||
}),
|
}),
|
||||||
|
|
||||||
# Ward et al.: Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults
|
# Ward et al.: Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults
|
||||||
@@ -388,8 +390,8 @@ def main():
|
|||||||
fig.suptitle('Infection Fatality Ratio of COVID-19 vs. Seasonal Influenza')
|
fig.suptitle('Infection Fatality Ratio of COVID-19 vs. Seasonal Influenza')
|
||||||
ax.text(0, -0.11,
|
ax.text(0, -0.11,
|
||||||
'Source: https://github.com/mbevand/covid19-age-stratified-ifr\n'
|
'Source: https://github.com/mbevand/covid19-age-stratified-ifr\n'
|
||||||
'Note: the vertical lines on two COVID-19 IFR curves (Poletti and O’Driscoll) are caused by the IFR being\n'
|
'Note: the vertical lines on one COVID-19 IFR curve (Poletti) are caused by the IFR being\n'
|
||||||
'estimated to be zero by Poletti for age groups 0-19 and 20-49, and by O’Driscoll for 5-9 and 10-14.\n',
|
'estimated to be zero for age groups 0-19 and 20-49.\n',
|
||||||
transform=ax.transAxes, fontsize='small', verticalalignment='top',
|
transform=ax.transAxes, fontsize='small', verticalalignment='top',
|
||||||
)
|
)
|
||||||
ax.text(1, 1, 'Created by: Marc Bevand — @zorinaq',
|
ax.text(1, 1, 'Created by: Marc Bevand — @zorinaq',
|
||||||
|
|||||||
Reference in New Issue
Block a user